SEARCH

SEARCH BY CITATION

References

  • 1
    Zagars GK, Sherman NE, Babaian RJ. Prostate-specific antigen and external beam radiotherapy in prostate cancer. Cancer 1991; 67: 41220.
  • 2
    Russell KJ, Dunatov C, Hagerman MD, Friggeth JT, Polissar L, Pelton J, et al. Prostate-specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1992; 146: 104652.
  • 3
    Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992; 10: 120817.
  • 4
    Meek AG, Park TL, Oberman E, Wielopolski L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1990; 19: 73341.
  • 5
    Landmann C, Hunig R. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys 1989; 17: 10736.
  • 6
    Zagars GK, von Eschenbach AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiotherapy. Cancer (in press).
  • 7
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 90916.
  • 8
    Kaplan ID, Cox RS, Bagshaw MA. A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy. Cancer 1991; 68: 4005.
  • 9
    Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: I. Untreated patients. J Urol 1989; 141: 10705.
  • 10
    Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23: 4753.
  • 11
    Zagars GK. The prognostic significance of a single serum prostate-specific antigen value beyond 6 months after radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys (in press).
  • 12
    Brawn PN, Ayala AG, von Eschenbach AC, Hussey DH, Johnson DE. Histologic grading study of prostate adenocarcinoma: the development of a new system and comparison with other methods. A preliminary study. Cancer 1982; 49: 52532.
  • 13
    Glantz SA, Slinker BK. Primer of applied regression and analysis of variance. New York: McGraw-Hill, 1990: 464511.
  • 14
    Dixon WJ. BMDP statistical software manual. vols. 1 and 2. Berkley: University of California Press, 1990: 80250.
  • 15
    Norusis MJ. SPSS for windows: advanced statistics, release 5. Chicago: SPSS, 1992: 21532.
  • 16
    Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991: 122395.
  • 17
    Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker, 1991: 5123.
  • 18
    Zagars GK, von Eschenbach AC, Ayala AG, Schultheiss TE: The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 1991; 6: 23707.
  • 19
    Oesterling JE, Chan DW, Epstein JI, Kimball AW, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988; 139: 76672.
  • 20
    Meyer JS. Potential value of cell kinetics in management of cancers of unknown origin. Semin Oncol 1982; 9: 5136.
  • 21
    Helpap B, Stiens R, Bruhl P. The proliferative pattern of the prostatic carcinoma before and under hormonal treatment. Z Krebsforsch 1976; 87: 31120.
  • 22
    Scrivner DL, Meyer JS, Rujanavech N, Fathman A, Scully T. Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies. J Urol 1991; 146: 10349.
  • 23
    Nemoto R, Uchida K, Shimazui T, Hattori K, Koiso K, Harada M. Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma. J Urol 141: 1989; 33740.
  • 24
    Charbit A, Malaise EP, Tubiana M. Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer 1971; 7: 30715.
  • 25
    Steel GG. Growth kinetics of tumors: cell population kinetics in relation to the growth and treatment of cancer. Oxford: Clarendon Press, 1977: 185216.
  • 26
    Steel G. Cell loss from experimental tumors. Cell Tissue Kinet 1968; 1: 193207.
  • 27
    Perez C. Presidential address of the 24th Annual Meeting of the American Society of Therapeutic Radiologists. Carcinoma of the prostate: a vexing biological and clinical enigma. Int J Radiat Oncol Biol Phys 1983; 9: 142738.
  • 28
    Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate: an analysis of 551 patients treated with external beam radiation. Cancer 1987; 60: 148999.
  • 29
    Cox JD, Kline RW. The lack of prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol 1983; 1: 23742.